Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Parathyroid Hormone

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    $ API Ref.Price (USD/KG) : 3,700,927Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Takeda to stop making parathyroid drug Natpara after production challenges
    Takeda to stop making parathyroid drug Natpara after production challenges

    05 Oct 2022

    // BIOPHARMADIVE

    https://www.biopharmadive.com/news/takeda-stop-production-natpara-hypoparathyroidism/633295/

    BIOPHARMADIVE
    05 Oct 2022
    Share Share
    Takeda's rare disease unit suffers on hemophilia, Natpara recall
    Takeda's rare disease unit suffers on hemophilia, Natpara recall

    01 Nov 2019

    // Angus Liu FIERCE PHARMA

    https://www.fiercepharma.com/pharma/hemophilia-rivalry-pressures-post-shire-takeda-but-ceo-weber-points-to-14-drugs-for-growth

    Angus Liu FIERCE PHARMA
    01 Nov 2019
    Share Share
    Enforcement Report - Week of October 2, 2019
    Enforcement Report - Week of October 2, 2019

    02 Oct 2019

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-october-2-2019-1570003052.pdf

    FDA
    02 Oct 2019
    Share Share
    Rhetoric or a real threat? Track your pharma politics here
    Rhetoric or a real threat? Track your pharma politics here

    16 Sep 2019

    // Eric Sagonowsky FIERCE PHARMA

    https://www.fiercepharma.com/pharma/rhetoric-or-a-real-threat-track-weekly-drug-pricing-developments-us

    Eric Sagonowsky FIERCE PHARMA
    16 Sep 2019
    Share Share
    Takeda recalls eye drug Natpara, warns patients not to abruptly stop treatment 
    Takeda recalls eye drug Natpara, warns patients not to abruptly stop treatment 

    07 Sep 2019

    // Eric Palmer FIERCEPHARMA

    https://www.fiercepharma.com/manufacturing/takeda-recalls-eye-drug-natpara-but-warns-patients-not-to-abruptly-stop-treatment

    Eric Palmer FIERCEPHARMA
    07 Sep 2019
    Share Share
    Takeda Issues US Recall of NATPARA® (parathyroid hormone)
    Takeda Issues US Recall of NATPARA® (parathyroid hormone)

    06 Sep 2019

    // FDA

    https://www.pharmacompass.com/pdf/news/takeda-issues-us-recall-of-natpara-parathyroid-hormone-1568769281.pdf

    FDA
    06 Sep 2019
    Share Share